GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) announced it will release its third quarter 2020 financial results on November 5, 2020, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update. GBT focuses on developing treatments for sickle cell disease (SCD) and has introduced the FDA-approved therapy Oxbryta. The company is also advancing its pipeline with inclacumab, targeting pain crises in SCD.

Global Blood Therapeutics (GBT) has announced its participation in the 15th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT), showcasing real-world effectiveness data of Oxbryta (voxelotor) in treating sickle cell disease (SCD). The data indicates that voxelotor raised hemoglobin levels by over 1 g/dL in patients, consistent with earlier clinical trial results. Additionally, a case study highlighted the drug's role in improving hemoglobin levels and clinical status in a COVID-19 patient, avoiding the need for blood transfusions. GBT also published a report on the SCD landscape in Europe.

Global Blood Therapeutics (GBT) has received the 2020 Rare Impact Award from NORD for its innovative therapy Oxbryta (voxelotor), recognized for addressing unmet needs in the treatment of sickle cell disease (SCD). This award was presented during NORD's annual summit on October 9, 2020. Oxbryta is the first therapy that directly inhibits hemoglobin polymerization, approved for patients aged 12 and older. GBT aims to expand its use to younger patients and continues its commitment to improving treatments for SCD.

Global Blood Therapeutics (GBT) has announced the granting of stock options and restricted stock units to 20 new employees as part of its Amended and Restated 2017 Inducement Equity Plan. On October 1, 2020, the company issued options for 12,000 shares at an exercise price of $57.96 and 93,950 shares in restricted stock units. This move is intended to attract new talent in accordance with NASDAQ Listing Rule 5635(c)(4). GBT focuses on innovative treatments for sickle cell disease, including its FDA-approved drug Oxbryta (voxelotor).

Global Blood Therapeutics (GBT) and the Sickle Cell Disease Association of America (SCDAA) are hosting the 9th Annual Sickle Cell Disease Therapeutics Conference on September 15, 2020. The virtual event, coinciding with National Sickle Cell Awareness Month, will feature keynote speaker Admiral Brett P. Giroir, M.D. Discussions will focus on SCD treatment advancements and the COVID-19 impact on patients. The conference aims to foster dialogue for improved healthcare strategies.

Global Blood Therapeutics (GBT) has announced an exclusive distribution agreement with Biopharma-Middle East and Africa to distribute Oxbryta (voxelotor) in the GCC region, where over 100,000 individuals are affected by sickle cell disease (SCD). Oxbryta is a first-in-class, once-daily oral therapy that addresses hemoglobin polymerization, a key issue in SCD. With prior FDA approval in the U.S. in 2019, this partnership aims to expand access to this treatment for patients in need across Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.

Global Blood Therapeutics (GBT) has granted options to seven new employees to purchase a total of 11,678 shares at $60.45 each, along with restricted stock units for 46,585 shares. These awards comply with NASDAQ Listing Rule 5635(c)(4) and are part of GBT's Amended and Restated 2017 Inducement Equity Plan. GBT is focused on developing treatments for sickle cell disease and has FDA-approved Oxbryta as its flagship product. The plan aims to attract talent to enhance GBT's product pipeline and overall impact in the biopharmaceutical sector.

Global Blood Therapeutics (GBT) reported Q2 2020 net revenues of $31.5 million from Oxbryta® with approximately 1,000 new patient prescriptions. Despite COVID-19's impact, GBT noted stabilization in new prescriptions due to virtual engagements. The company plans to submit regulatory applications for Oxbryta for younger patients in the U.S. and seeks marketing authorization in Europe by mid-2021. R&D expenses decreased to $34.1 million, while SG&A expenses rose to $49.1 million. GBT reported a net loss of $52.8 million and held $574.2 million in cash as of June 30, 2020.

Global Blood Therapeutics (GBT) has announced participation in key investor conferences. Management will engage in virtual fireside chats at the William Blair Biotech Focus Conference on August 6, Wedbush PacGrow Healthcare Virtual Conference on August 11, and Canaccord Genuity 40th Annual Growth Virtual Conference on August 13. These events will be webcast live on GBT's website, with replays available for a month post-event. GBT focuses on developing treatments for sickle cell disease, including the FDA-approved Oxbryta and other drug candidates.